Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Taiho Oncology, Inc.

Community Practice Connections™: 18th Annual Meeting of the International Society of Gastrointestinal Oncology®

Release Date: November 23, 2021
Expiration Date: November 23, 2022

Activity Overview

Gastrointestinal (GI) malignancies continue to be a major contributor to cancer-related morbidity and mortality. Recent advances like novel molecular testing modalities, new treatment options, and improved management principles have contributed to significant improvement in patient outcomes.
 
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 18th Annual Meeting of the International Society of Gastrointestinal Oncology, held in October 2021. This multimedia activity is ideal for community-based clinicians, focusing on key takeaways and practical advice for managing patients with GI cancer, using written summaries supplemented by interviews with world experts in the treatment of these tumors. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
 

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Taiho Oncology, Inc.
 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.



Target Audience

This educational activity is directed toward oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in GI oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe current standards of care for treatment of GI malignancies
  • Discuss recent advances and innovations in the management of GI malignancies
  • Analyze clinical trial data that may impact treatment decision-making in GI oncology
  • Implement a multimodal approach to the treatment of GI malignancies, including gastric, pancreatic, and colorectal cancers, hepatocellular carcinoma, and cholangiocarcinoma

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. 
 

Faculty

Tanios Bekaii-Saab, MD, FACP
Tanios Bekaii-Saab, MD, FACP
Professor of Medicine
Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Consultant, Division of Hematology/Oncology
Mayo Clinic Cancer Center
Consortium Chair
Academic and Community Cancer Research United
Phoenix, AZ

Disclosures: Grant/Research Support: (to institution) Agios Pharmaceuticals Inc.; Arrys Therapeutics, Inc.; Arcus Biosciences; Atreca, Inc.; Boston Biomedical, Inc.; Bayer HealthCare Pharmaceuticals Inc.; Amgen Inc.; Merck & Co., Inc.; Celgene Corporation; Eli Lilly and Company; Ipsen Biopharmaceuticals; Clovis Oncology; Seagen Inc.; Genentech, Inc./Roche; Novartis Pharmaceuticals Corporation; Mirati Therapeutics Inc.; Merus; AbGenomics International Inc.; Incyte Corp.; Pfizer Inc.; Bristol Myers Squibb Company; Consultant: Ipsen Biopharmaceuticals; Array BioPharma; Pfizer Inc.; Seagen Inc.; Bayer HealthCare Pharmaceuticals Inc.; Genentech, Inc./Roche; Incyte Corp.; Merck & Co., Inc. (consulting/to institution) AbbVie Inc.; Boehringer Ingelheim; Janssen Pharmaceuticals; Eisai Co., Ltd.; Daichii Sankyo, Inc.; Natera Inc.; Treos Bio Limited; Celularity Inc.; Exact Sciences Corp.; Swedish Orphan Biovitrum AB; BeiGene; Xilis, Inc.; AstraZeneca; Foundation Medicine, Inc. (consulting, to self); Other: AstraZeneca; Eli Lilly and Company; Pancreatic Cancer Action Network; Globe Health Institute (IDMC/DSMB, to self); Imugene Ltd.; Immuneering Corporation; Sun BioPharma, Inc. (scientific advisory board); Inventions/Patents: WO/2018/183488 and WO/2019/055687.
 

Daniel Catenacci, MD
Daniel Catenacci, MD
Associate Professor of Medicine
Section of Hematology and Oncology
Director, Gastrointestinal
Oncology Program
Assistant Director, Translational Research
University of Chicago Comprehensive Cancer Center
The University of Chicago Medical Center &
Biological Sciences
Chicago, IL

Disclosures: Consultant: Genentech, Inc./Roche; Eli Lilly and Company; Merck & Co., Inc.; Daiichi Sankyo, Inc.; Tempus, Inc.; Guardant Health, Inc.; Bristol Myers Squibb Company; Five Prime Therapeutics, Inc.; Seagen Inc.; Amgen Inc.; Taiho Oncology, Inc.; Astellas Pharma Inc.; Gritstone bio; Pieris Pharmaceuticals, Inc.; Zymeworks Inc.; Basilea Pharmaceutica AG; QED Therapeutics, Inc.; Arcus Biosciences; Foundation Medicine, Inc.; Tempus, Inc.; Guardant Health, Inc.; Archer Pharmaceuticals, Inc.; Natera Inc.; Speaker’s Bureau: Genentech, Inc./Roche; Eli Lilly and Company; Merck & Co., Inc.; Tempus, Inc.; Guardant Health, Inc.
 

Kristen Ciombor, MD, MSCI
Kristen Ciombor, MD, MSCI
Assistant Professor of Medicine
Division of Hematology/Oncology
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, TN

Disclosures: Grant/Research Support: Bristol Myers Squibb Company; Array BioPharma; Incyte Corp.; Daiichi Sankyo, Inc.; NuCana plc; Merck & Co., Inc.; Pfizer Inc.; Calithera Biosciences, Inc. (research funding to institution); Consultant: Natera Inc.; Array BioPharma; Merck & Co., Inc.
 

Eileen M. O’Reilly, MD
Eileen M. O’Reilly, MD
Winthrop Rockefeller Endowed Chair in
Medical Oncology
Section Head, Hepatopancreaticobilary & Neuroendocrine Cancers
Gastrointestinal Oncology Service
Co-Director, Medical Initiatives
David M. Rubenstein Center for Pancreatic
Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Disclosures: Grant/Research Support: Genentech, Inc./Roche; Celgene/Bristol Myers Squibb; BioNTech SE; BioAtla Inc.; AstraZeneca; Arcus Biosciences; Elicio Therapeutics Inc.; Parker Institute for Cancer Immunotherapy; Pertzye; Consultant: CytomX Therapeutics (DSMB); Rafael Pharmaceuticals (DSMB); Swedish Orphan Biovitrum AB; Silenseed Ltd.; Tyme Technologies Inc.; Seagen Inc.; Molecular Templates, Inc.; Boehringer Ingelheim; BioNTech SE; Ipsen, Inc.; Polaris Inc.; Merck & Co., Inc.; AstraZeneca; Noxxon Pharma; BioSapien Inc.; Bayer HealthCare Pharmaceuticals Inc. (spouse); Genentech, Inc./Roche (spouse); Celgene Corporation/Bristol Myers Squibb (spouse); Eisai Co., Ltd. (spouse).
 

Rachna Shroff, MD, MS
Rachna Shroff, MD, MS
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
Interim Director, Arizona Clinical Trials
Network
Vice Chair, Clinical Research, Department of
Medicine
Associate Professor of Medicine
Division of Hematology/Oncology
University of Arizona Cancer Center
Tucson, AZ

Disclosures: Grant/Research Support: Pieris Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Rafael Pharmaceuticals; Consultant: Merck & Co., Inc.; Seagen Inc.; Exelixis, Inc.; QED Therapeutics, Inc.; Debiopharm Group; Agios Pharmaceuticals Inc.; Clovis Oncology; Incyte Corporation.
 

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
 


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By